Issues

RAS/ERK pathway inhibitors induce CXCR2 ligand production by tumor cells, evoking gMDSC influx and impairing treatment response, while CXCR2 inhibition blocks immigration of select gMDSCs, leading to reactivation of antitumor T cells and enhanced treatment efficacy.

Up to 20% of patients with hematologic cancers exhibited persistent, symptomatic COVID-19 infection, which was particularly common in patients receiving B-cell depleting therapies.

In a phase I dose escalation/expansion study, use of the HER3-DXd antibody drug conjugate showed clinical activity in EGFR TKI-resistant, EGFR-mutant non–small cell lung cancer, presenting a future option for drug-resistant cancers.

Cyclic, severe calorie restriction is safe in patients with cancer, and it reduces blood glucose and growth factor concentration as well as activates cytotoxic immune cells in peripheral blood and in the tumor microenvironment.

Low-dose radiotherapy triggered T-cell infiltration into poorly inflamed tumors and reprogrammed both the adaptive and innate immune landscape to allow responsiveness to combinatorial immunotherapy.

Multisector analysis of malignant brain tumors highlights substantial differences in immunogenomic landscapes, with gliomas harboring greater spatial heterogeneity at a genomic, neoantigen, and T-cell repertoire level.

Clonal oncogenic somatic single-nucleotide and copy number variants with pathogenic potential and high-allele frequency are present in the nondiseased human brain and show patterns resembling those found in brain tumors.

GDC-0077 was discovered to more potently inhibit PI3K signaling as well as reduce cell viability through p110α degradation, making it more effective at prolonging PI3K pathway suppression than other PI3K inhibitors.

Profiling of DNMT3A variants revealed a large portion with dramatic loss of DNA methyltransferase activity and protein stability, which enabled the risk stratifi cation of malignancy development and revealed a molecular mechanism of regulated DNMT3A turnover.